Anuh Pharma Limited has informed the Exchange regarding 're-appointment of Cost Auditor.'.
ANUHPHR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Anuh Pharma Limited's Board of Directors approved the audited financial results for FY2026. Revenue from operations grew 16.6% year-on-year to Rs. 77,165.74 Lakhs, driven by higher sales volumes. However, profit after tax declined 13.3% to Rs. 4,104.61 Lakhs compared to Rs. 4,735.19 Lakhs in FY2025, impacted by increased costs and lower other income. EBITDA margin contracted to 8.56% from 10.64% previously. The Board recommended a dividend of Rs. 1.50 per equity share (30% payout on Rs. 5 face value), subject to shareholder approval at the AGM on 12th August 2026. Additionally, the Board re-appointed two non-executive directors (Mr. Bipin Shah and Mr. Arun Todarwal), appointed a new General Manager-Quality, and re-appointed Ankit Kishor Chande as Cost Auditor for FY2026-27. Nine promoter group shareholders holding 0.95% of shares have sought re-classification to public category.
While revenue growth is positive, the decline in profitability and margin contraction may concern investors. The dividend recommendation provides some support. The promoter re-classification requests suggest potential reduction in promoter holding, which could impact stock sentiment. Overall, this is a mixed results announcement.